Richard R. Burgess

Atterx Biotherapeutics, Inc. develops novel antibacterial technologies. It developed two products to fight multi-drug resistant, Gram negative bacteria. The first product, C-1205 utilizes bacterial interference technology to prevent catheter associated urinary tract infections and GN-4474 has been developed using this technology to target Gram negative bacteria. It has been shown to be effective in animal infection models and an IND filing is expected in 2015. The company was founded by Richard R. Burgess and Marcin Filutowicz in 2001 and is headquartered in Madison, WI.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

The University of Wisconsin Biotechnology Center provides core facilities for various biotechnology services such as bioinformatics, next-generation sequencing, genome editing, animal models, gene expression, mass spectrometry, and isotope ratio mass spectrometry. The center is based in Madison, WI. The center also offers outreach programs such as Biogarage and Biotrek. Payment instructions are included on the invoice for external customers.

NeoClone Biotechnology International LLC engages in the production and supply of monoclonal antibody products. The firm offers antibodies to bacterial transcription proteins, RNA polymerase II, bacterial toxins, eukaryotic transcription proteins, neural proteins, cancer proteins, cardiac biomarkers, and interferon gamma, as well as offers cancer antibodies and Softag products. It provides contract monoclonal antibodies for companies and individual researchers, as well as for university and industry researchers. The company was founded in 1999 by Mark Jackson, Donal Kaehler, David Largaspaeda and Deven McGlenn and is headquartered in Madison, WI.